BioCentury
ARTICLE | Tools & Techniques

The mechanical chemist

April 4, 2013 7:00 AM UTC

Cyclofluidic Ltd. has published proof-of-concept data showing that its automated microfluidic lead optimization platform can identify new BCR-ABL tyrosine kinase inhibitors.1 The company's next step is showing that automated hit-to-lead optimization will work with other targets and compound classes.

Cyclofluidic, a joint venture between Pfizer Inc. and UCB Group, was formed in 2008 to develop and commercialize drug screening technology centered around a microfluidic robot that integrates the four steps of traditional SAR studies into a single automated cycle (see "Automated SAR studies"). The biotech also received an undisclosed amount of seed funding from the U.K.'s Technology Strategy Board...